

Diastereoselective Synthesis of the Hydroxyethylene
Dipeptide Isostere of Leu-Val

Takahide NISHI,* Mitsuru KATAOKA, and Yasuhiro MORISAWA
Medicinal Chemistry Research Laboratories, Sankyo Co., Ltd.,
1-2-58 Hiromachi Shinagawa-ku, Tokyo 140

The synthesis of hydroxyethylene dipeptide isostere of Leu-Val, a transition-state mimic, is described. The key steps of this synthetic approach are the homogeneous asymmetric hydrogenation of γ -keto esters by BINAP-Ru(II) complex, and the construction of a 2(S)-isopropyl unit.

Renin is an aspartic proteinase responsible for cleaving a decapeptide fragment from angiotensinogen and participates in the regulation of blood pressure. The search for renin inhibitors has intensified in recent years for control of hypertension. Numerous approaches to the design of renin inhibitors have been investigated. The most notable approach has been based upon the concept of a transition-state analogues,¹⁾ such as the statine analogue (1)²⁾ and the hydroxyethylene dipeptide isostere at the scissile site (2)³⁾ (Fig. 1).





Fig. 1.

For the stereoselective introduction of the 2(S)-isopropyl unit, syn- γ -lactones (4a,b) are apparently useful precursors, since stereoselective trans alkylation at C-2 could be expected.⁴⁾ In our previous report, syn- γ -lactones were prepared starting from diacetone-D-glucose as the chiral building block, although this synthetic route required a number of steps.⁵⁾


We report here an alternative synthetic route to syn- γ -lactones based on the reduction of the γ -keto esters (3a,b). The γ -keto esters (3a,b) were obtained in good yield from the corresponding N-Boc-L-amino aldehyde in three steps.⁶⁾ As shown in Table 1, reduction of γ -keto esters (3a,b) with reagents followed by cyclization produced the corresponding γ -lactones (4a,b and 5a,b). Several reducing reagents under various conditions were tried for the stereoselective reduction. Reduction with the periodic trend of borohydride reagents (runs 1-5) provided the undesired anti- γ -lactone as the major product regardless of the reagent. Further, reduction with bulky reagents resulted in low yield with low stereoselectivity

lactones (6a,b) in good yield (Scheme 1).⁹⁾ The diastereomers 6 and 7 can be conveniently separated by column chromatography on SiO₂.



Scheme 1.

At first we examined the conversion of 6 and 7 into 11 by an initial dehydration and subsequent hydrogenation of 6a,b. Treatment of 6a,b with POCl₃ in pyridine followed by a catalytic hydrogenation of 8a,b by Pd on BaSO₄ gave undesired diastereomers 9a,b⁹⁾ (Scheme 2). Whose structures were determined by X-ray crystallographic analysis. Attempts to epimerize the isopropyl unit of 9a,b with DBU/DMF at 100 °C was not satisfactory to give a mixture of equilibrium products in a ratio of β/α isomers (1 : 2).




a) POCl₃, pyridine, 0 °C. b) H₂(4 atm)/Pd on BaSO₄, AcOEt.

Scheme 2.

Next, deoxygenation of 6a,b was studied to obtain 11a,b. Mild conditions were required in this reaction, because the retro-aldol reaction could easily occur under basic conditions.¹⁰⁾ Finally, this was accomplished via 2 step sequence of reactions reported by Dolan and MacMillan.¹¹⁾ Treatment of 6a,b with methyl oxalyl chloride gave 10a,b in good yield. Then reaction of 10a,b with tributyltin hydride and AIBN in refluxing toluene gave the desired 2(S)-isopropyl-γ-lactones (11a,b).⁹⁾ The γ-lactones 11a,b were readily converted to hydroxyamides 12a,b by treatment with methylamine in good yield as shown in Scheme 3.⁹⁾ In conclusion, starting from γ-keto esters (3a,b), a short and diastereoselective synthetic route to the hydroxyethylene dipeptide isostere of Leu-Val was established. The biological activities of low molecular-weight renin inhibitors which contain these fragment will be reported elsewhere.

We are grateful to Prof. Ryoji Noyori and Dr. Masato Kitamura, Nagoya University for useful discussions about the homogeneous asymmetric hydrogenation.



a) MeOCOCOCI, NEt₃, cat. DMAP, THF, 0 °C. b) *n*-Bu₃SnH, AIBN, PhMe. c) MeNH₂, MeOH.

Scheme 3.

References

- 1) L. Pauling, Chem. Eng. News., 24, 1375 (1946); R. Wolfenden, Nature, 223, 704 (1969); J. Marciniszyn, J. A. Hartsuck, and J. Tang, J. Biol. Chem., 251, 7088 (1976).
- 2) Syntheses of statine and its analogues: T. Nishi, M. Kitamura, T. Ohkuma, and R. Noyori, Tetrahedron Lett., 29, 6327 (1988), and references cited therein.
- 3) S. Thaisrivongs, D. T. Pals, D. W. Harris, W. M. Kati, and S. R. Turner, J. Med. Chem., 29, 2088 (1986); P. Bühlmayer, A. Caselli, W. Fuhrer, R. Gösche, V. Rasetti, H. Rüeger, J. L. Stanton, L. Criscione, and J. M. Wood, ibid., 31, 1839 (1988). Syntheses: B. E. Evans, K. E. Rittle, C. F. Homnick, J. P. Springer, J. Hirshfield, and D. F. Veber, J. Org. Chem., 50, 4615 (1985); D. J. Kempf, ibid., 51, 3921 (1986); A. H. Fray, R. L. Kaye, and E. F. Kleinman, ibid., 51, 4828 (1986); M. W. Holladay, F. G. Salituro, and D. H. Rich, J. Med. Chem., 30, 374 (1987); P. G. M. Wuts, S. R. Putt, and A. R. Ritter, J. Org. Chem., 53, 4503 (1988); P. K. Chakravarty, S. E. de Laszlo, C. S. Sarnella, J. P. Springer, and P. F. Schuda, Tetrahedron Lett., 30, 415 (1989); P. Herold, R. Duthaler, G. Rihs, and C. Angst, J. Org. Chem., 54, 1178 (1989); M. Shiozaki, T. Hata, and Y. Furukawa, Tetrahedron Lett., 30, 3669 (1989).
- 4) S. Takano, W. Uchida, S. Hatakeyama, and K. Ogasawara, Chem. Lett., 1982, 733; A. H. Davidson, C. D. Floyd, A. J. Jones, and P. L. Myers, J. Chem. Soc., Chem. Commun., 1985, 1662.
- 5) H. Yanagisawa, T. Kanazaki, and T. Nishi, Chem. Lett., 1989, 687.
- 6) i) lithium ethyl propiolate, THF, -78 °C, ii) H₂ (4 atm)/Pd on BaSO₄, AcOEt, iii) PCC, molecular sieves 3A, CH₂Cl₂.
- 7) R. Noyori, T. Ohkuma, M. Kitamura, H. Takaya, N. Sayo, H. Kumobayashi, and S. Akutagawa, J. Am. Chem. Soc., 109, 5856 (1987).
- 8) N. Nimura, H. Ogura, and T. Kinoshita, J. Chromatogr., 202, 375 (1980).
- 9) Satisfactory spectral (NMR, IR, MS) and analytical data were obtained for all new compounds.
6a, mp 123-125 °C, [α]_D²⁰ -20.6° (c 1, MeOH). **6b**, mp 93-95 °C, [α]_D²⁰ -27.5° (c 1, MeOH). **7a**, mp 141-143 °C, [α]_D²⁰ -30.4° (c 1, MeOH). **7b**, mp 113-115 °C, [α]_D²⁰ -35.1° (c 1, MeOH). **9a**, mp 133-134 °C, [α]_D²⁰ -23.4° (c 1, MeOH). **9b**, mp 94-96 °C, [α]_D²⁰ -32.0° (c 1, MeOH). (lit.³⁾ mp 94-96 °C, [α]_D²⁰ -32.4° (c 1, EtOH). **11a**, mp 114-116 °C, [α]_D²⁰ -30.6° (c 1, MeOH). **11b**, mp 144-146 °C, [α]_D²⁰ -36.6° (c 1, MeOH). (lit.³⁾ mp 146-148 °C, [α]_D²⁰ -39.4° (c 1, EtOH). **12a**, mp 154-157 °C, [α]_D²⁰ -42.0° (c 0.75, MeOH). **12b**, mp 149-151 °C, [α]_D²⁰ -51.9° (c 1, MeOH).
- 10) We examined Barton's method (NaH, CS₂, MeI); however the retro-aldol reaction predominated, and the other modification methods were unsuccessful.
- 11) S. C. Dolan and J. MacMillan, J. Chem. Soc., Chem. Commun., 1985, 1588.

(Received August 17, 1989)